Venus Remedies Ltd Gains 10.03%: 5 Key Factors Driving the Surge

8 June 2026: Surge to New 52-Week and All-Time Highs with Upper Circuit

Venus Remedies Ltd began the week on a strong note, surging 3.02% to close at Rs.1,686.55, hitting an intraday 52-week high of Rs.1,718.95 and an all-time high of Rs.1,702.95. The stock hit its upper circuit limit, closing at Rs.1,715.10, a 5.0% gain, amid robust buying momentum and increased delivery volumes. This rally marked the 11th consecutive day of gains, delivering a remarkable 66.64% return over that period, vastly outperforming the Pharmaceuticals & Biotechnology sector and the broader market, which declined 1.33% on the Sensex.

Technical indicators were overwhelmingly bullish, with the stock trading above all key moving averages and supported by positive MACD, Bollinger Bands, and On-Balance Volume signals. Institutional investors increased their stake by 0.72% in the previous quarter, reflecting growing confidence in the company’s fundamentals.

9 June 2026: New High Followed by Sharp Correction and Lower Circuit

The stock reached a new 52-week and all-time high of Rs.1,729.95 intraday but closed lower at Rs.1,602.25, down 5.00%, after hitting the lower circuit amid heavy selling pressure. The intraday volatility was significant, with a range from Rs.1,603 to Rs.1,729.95. Despite the sharp correction, Venus Remedies remained above all key moving averages, maintaining its technical uptrend.

This sudden reversal followed an extended rally and was driven by profit booking and panic selling, with delivery volumes rising sharply. The stock underperformed both its sector and the Sensex on this day, which gained 0.88%. The lower circuit event highlighted the volatility risks associated with micro-cap stocks despite strong fundamentals.

10 June 2026: Recovery with Upper Circuit and Strong Quarterly Results

Venus Remedies rebounded strongly, hitting the upper circuit limit again to close at Rs.1,684, a 5.00% gain from the previous close. The day’s trading saw a wide range from Rs.1,577.65 to Rs.1,691.20, reflecting renewed investor optimism. Delivery volumes increased by over 20%, signalling genuine accumulation.

Financially, the company reported record quarterly net sales of Rs.259.40 crores and a peak PBDIT of Rs.63.42 crores, with an operating margin of 24.45%. Net profit surged to Rs.47.50 crores, and EPS reached Rs.35.53, the highest recorded. Return on capital employed stood at 19.85%, underscoring efficient capital utilisation. Despite a tightening cash position, the overall financial trend remained positive, supporting the stock’s technical strength.

12 June 2026: New 52-Week High and Upper Circuit Amid Sustained Momentum

Venus Remedies Ltd continued its upward trajectory, hitting a new 52-week and all-time high of Rs.1,799 intraday and closing near the upper circuit at Rs.1,801.25, a 4.94% gain on the day. The stock outperformed the Sensex, which rose 2.20%, and the Pharmaceuticals & Biotechnology sector. This marked the third consecutive day of gains, with a cumulative 7.66% rise over this period.

Technical indicators remained strongly bullish, with the stock trading above all major moving averages and supported by positive MACD, Bollinger Bands, and On-Balance Volume signals. The Relative Strength Index showed a neutral weekly signal but a bearish monthly reading, suggesting some caution over the longer term.

Financially, the company remains net-debt free with strong growth metrics: operating profit annualised growth of 45.72%, net profit growth of 126.19% in the latest quarter, and a return on equity of 15.5%. Institutional investors increased their stake to 4%, reflecting sustained confidence. The company holds a Mojo Score of 74.0 with a Buy rating upgraded on 12 March 2026.

Key Takeaways

Venus Remedies Ltd demonstrated exceptional strength this week, gaining 10.03% and outperforming the Sensex by a wide margin. The stock’s ability to hit multiple new 52-week and all-time highs, including three upper circuit hits, reflects strong investor demand and positive market sentiment.

Robust quarterly financial results, including record net sales and profit margins, underpin the rally. The company’s net-debt-free status and improving return metrics such as ROCE and ROE further support its growth narrative. Institutional investor participation has increased, signalling confidence in the company’s fundamentals.

However, the sharp correction and lower circuit hit on 9 June highlight the volatility risks inherent in micro-cap stocks. Investors should be mindful of liquidity constraints and potential price swings despite the strong technical and fundamental backdrop.

Technical indicators remain broadly bullish, with the stock trading above all key moving averages and supported by positive momentum oscillators. The slight caution signalled by the monthly RSI suggests monitoring for potential longer-term consolidation.

Conclusion

Venus Remedies Ltd’s performance over the week ending 12 June 2026 underscores its position as a high-growth micro-cap stock within the Pharmaceuticals & Biotechnology sector. The stock’s sustained upward momentum, supported by strong financial results and increasing institutional interest, has driven significant outperformance relative to the broader market.

While the recent volatility and circuit hits highlight the need for cautious risk management, the company’s robust fundamentals and positive technical outlook suggest continued investor interest. Venus Remedies remains a noteworthy example of a micro-cap stock delivering multibagger returns through consistent operational excellence and market leadership.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →